KIAA0319L and Duchenne muscular dystrophy: MuSCs, which are refractory to AAV transduction, express low levels of endogenous Aavr. Targeting muscle with AAV gene therapy is relevant for the treatment of inherited disorders of progressive muscular weakness, including Duchenne muscular dystrophy and spinal muscular atrophy.